Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12782918rdf:typepubmed:Citationlld:pubmed
pubmed-article:12782918lifeskim:mentionsumls-concept:C0030567lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C0003596lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C0023570lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:12782918lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:12782918pubmed:issue3lld:pubmed
pubmed-article:12782918pubmed:dateCreated2003-6-3lld:pubmed
pubmed-article:12782918pubmed:abstractTextThe authors investigated the long-duration response to levodopa in advanced Parkinson's disease. Eight patients with advanced Parkinson's disease disabled by severe ON/OFF fluctuations treated by chronic daytime subcutaneous apomorphine infusion with supplemental oral levodopa were studied. On day 1, oral levodopa was withdrawn at 4:00 pm and on the following morning subcutaneous apomorphine infusion was continued at the same rate without levodopa therapy. While receiving apomorphine alone, seven of the eight patients turned ON, and their usual dyskinesias returned. The ON phase persisted for 60 to 100 minutes (mean, 185.7 minutes) but then, despite continued, constant-rate apomorphine infusion to stabilize plasma levels, switched to an OFF phase. The authors conclude that the clinical effect of apomorphine is sustained by levodopa long-duration response. This effect is probably the result of postsynaptic mechanisms. In patients with advanced Parkinson's disease, the long-duration response to levodopa is present although slightly diminished.lld:pubmed
pubmed-article:12782918pubmed:languageenglld:pubmed
pubmed-article:12782918pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782918pubmed:citationSubsetIMlld:pubmed
pubmed-article:12782918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782918pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12782918pubmed:statusMEDLINElld:pubmed
pubmed-article:12782918pubmed:issn0362-5664lld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:BerardelliAlf...lld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:VaccaLauraLlld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:StocchiFabriz...lld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:RuggieriStefa...lld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:BarbatoLucaLlld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:MongeAlessand...lld:pubmed
pubmed-article:12782918pubmed:authorpubmed-author:NorderaGiampi...lld:pubmed
pubmed-article:12782918pubmed:issnTypePrintlld:pubmed
pubmed-article:12782918pubmed:volume26lld:pubmed
pubmed-article:12782918pubmed:ownerNLMlld:pubmed
pubmed-article:12782918pubmed:authorsCompleteYlld:pubmed
pubmed-article:12782918pubmed:pagination151-5lld:pubmed
pubmed-article:12782918pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:meshHeadingpubmed-meshheading:12782918...lld:pubmed
pubmed-article:12782918pubmed:articleTitleApomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.lld:pubmed
pubmed-article:12782918pubmed:affiliationInstitute of Neurology IRCCS "NEUROMED," Pozzilli, Rome, Italy. fabrizio.stocchi@tin.itlld:pubmed
pubmed-article:12782918pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12782918pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12782918pubmed:publicationTypeComparative Studylld:pubmed